Aclaris Therapeutics, JAK Inhibitors

Aclaris Granted two Patents for JAK Inhibitors and Hair Loss Disorders

153 Comments

Aclaris Therapeutics’ latest e-mail from today morning contained a link to the following press release:

Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders

Quite often, when Aclaris discusses hair loss disorders in its press releases, they only mention alopecia areata (an autoimmune disorder that is responsible for hair loss in 2 percent or so of hair loss sufferers). However, this time they specifically mention androgenetic alopeia (AGA) six different times in their press release so it was worth writing a post on this development. Around 98 percent all men who suffer from hair loss suffer from AGA.

If you are new to this subject matter, make sure to read all the past posts on this blog regarding Aclaris.

Aclaris’ Latest Patents

The two patents that were just granted to Aclaris are highly detailed and informative:

Patent Number 9,737,469 — covers the use of tofacitinib, baricitinib, ruxolitinib and decernotinib, specifically for treating androgenetic alopecia.

Patent Number 9,730,877 — covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.

If you have time, I would encourage you to go through all the “US Patent Document” links in the upper part of the above two patent pages. Those reference documents go all the way from 1998 through 2016. If I had more time, I would search for “androgen” in all those documents and see what comes up.

Future Hair Loss Treatments, Poll

Which Future Hair Loss Treatments are you Optimistic About?

88 Comments
Tsuji Future Hair Loss Cure.
Dr. Tsuji’s Future Hair Loss Cure.

I was hoping to make a poll where users rank future hair loss cure related treatments. Via a score from 1-20 in terms of their most favorite one to least favorite one. However, the software did not allow for such a feature.

Make sure to check out my hair loss research page for other companies, labs and research centers that are working on new hair loss treatments. Note that I am not covering any alopecia areata related cures in this post.

Hair Loss Treatments Coming Soon

If I ask everyone to just pick their top 1 choice from the below list, a couple of the options will probably dominate way too much. So to keep things interesting, please choose at a bare minimum 3 of the below treatments/companies that you are hopeful will:

  • At least be close to release by the end of 2020. For the CRISPR/gene modification option, you can pick it even if you think it will only be realized 10 plus years down the road.
  • In their final versions, be at least slightly more effective then the only two currently FDA approved hair loss treatments (Finasteride and Minoxidil).

You can search this blog for any of the below names or acronyms if you are uncertain. Or you can post your questions in the comments to this post.

Which of the below future hair loss cure treatments are you most optimistic about? Pick at least 3.

Update: I had to delete the poll in 2018 due to some plugin issues. The results of the poll are summarized below. I bolded the 4 options (Shiseido, Tsuji, Aclaris and Follica) that received the most votes.

Total responses = 4,778.

  • Aclaris Therapeutics (Topical JAK Inhibitors) = 531 (11.1%).
  • Allergan (Bimatoprost Topical Prostaglandin Analog ) = 71 (1.5%).
  • Allergan (Setipiprant Oral Prostaglandin Antagonist) = 104 (2.2%).
  • BiologicsMD (Topical Beta-Catenin Protein Stimulation) = 28 (0.6%).
  • Cassiopea (Formerly Cosmo Pharmaceuticals — Breezula Topical Antiandrogen) = 56 (1.2%).
  • Chinese Surprise (Somewhere in China Something Secretive is Happening) = 98 (2.1%).
  • CRISPR (or Other Gene Modification Based Treatments) = 187 (3.9%).
  • Fidia Pharma (Brotzu DGLA Based Lotion) = 226 (4.7%).
  • Follica (Skin Disruption Plus Topical Compounds) = 398 (8.3%).
  • Follicum (Hair Follicle Stimulation Drug) = 106 (2.2%).
  • HairClone (Relatively new Company with Experienced Staff) = 113 (2.4%).
  • Histogen (Hair Stimulating Complex Injectable) = 343 (7.2%).
  • Kerastem and Others (Adipose Tissue Injection Based Treatments) = 39 (0.8%).
  • L’Oreal and Others (3D Printed Implantable Hair) = 199 (4.2%).
  • Samumed (Topical Wnt Pathway Modulation) = 169 (3.5%).
  • Shiseido/Replicel (Autologous Cell Replication Therapy) = 932 (19.5%).
  • Takashi Tsuji/Kyocera/Organ Technologies/RIKEN (Hair Follicle Regeneration) = 715 (15.0%).
  • New Age Hair Transplants (Including Potential Donor Hair Regeneration like Dr. Gho Claims, Body Hair Use, PRP Addition, Using Someone Else’s Hair etc…) = 124 (2.6%).
  • One Hundred Percent Scalp DHT Inhibition (Better Delivery Topical Dutasteride, Technion University DHT-Inactivating Enzyme, RISUG Male Contraceptive etc…) = 135 (2.8%).
  • Others. There are numerous scientists who have made major discoveries related to hair loss in recent years, and many of them aim to start product development asap = 204 (4.3%).